A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region
ChemBioChem · 2024
DOI: 10.1002/cbic.202400501 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Xiangru Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, CAS Research/Education Center for E…. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Molecular engineering enables the creation of aptamers with novel functions, but the prerequisite is a deep understanding of their structure and recognition mechanism. The cellular‐mesenchymal epithelial transition factor (c‐MET) is garnering significant attention due to the critical role of the c‐MET/HGF signaling pathway in tumor development and invasion. This study reports a strategy for constructing novel chimeric aptamers that bind to both c‐MET and other specific proteins. c‐MET was identified to be the molecular target of a DNA aptamer, HF3‐58, selected through cell‐SELEX. The binding structure and mechanism of HF3‐58 with c‐MET were systematically studied, revealing the scaffold, recognition, and redundancy regions. Through molecular engineering design, the redundancy region was replaced with other aptamers possessing stem‐loop structures, yielding novel chimeric aptamers with bispecificity for binding to c‐MET and specific proteins. A chimeric bispecific aptamer HF‐3b showed the ability to mediate the adhesion of T‐cells to tumor cells, suggesting the prospective utility in tumor immunotherapy. These findings suggest that aptamer HF3‐58 can serve as a molecular engineering platform for the development of diverse multifunctional ligands targeting c‐MET. Moreover, comprehensive understanding of the binding mechanisms of aptamers will provide guidance for the design of functional aptamers, significantly expanding their potential applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Acade…
- School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing, 100049, China.
- School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310013, China.
- The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Institute of Basic Medicine and Cancer (IBMC), Chin…
ORCID-Profile: Dihua Shangguan
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhang, X., Zhang, N., Sun, H., Li, D., Long, Z., Sheng, J., Zu, S., Bing, T., & Shangguan, D. (2024). A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region. ChemBioChem. https://doi.org/10.1002/cbic.202400501
Vancouver
Zhang X, Zhang N, Sun H, Li D, Long Z, Sheng J, et al. A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region. ChemBioChem. 2024. doi:10.1002/cbic.202400501
BibTeX
@article{Zhang2024,
author = {Zhang, Xiangru and Zhang, Nan and Sun, Haojun and Li, Dandan and Long, Zhenhao and Sheng, Jing and Zu, Shuang and Bing, Tao and Shangguan, Dihua},
title = {A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region},
journal = {ChemBioChem},
year = {2024},
doi = {10.1002/cbic.202400501}
}
EUVIMED